Schroder Investment Management Group
SKYE icon

Schroder Investment Management Group’s Skye Bioscience SKYE Stock Holding History

Schroder Investment Management Group’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-110,927
Closed -$207K – 1250
2025
Q1 		$207K Hold
110,927
– – ﹤0.01% 1159
2024
Q4 		$283K Hold
110,927
– – ﹤0.01% 1148
2024
Q3 		$416K Buy
+110,927
New +$622K ﹤0.01% 1126

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Schroder Investment Management Group's SKYE Position: Q2 2025 in Review

Schroder Investment Management Group sold out of Skye Bioscience (SKYE) in Q2 2025, closing a stake of 110,927 shares — an estimated $207K sold.

Schroder Investment Management Group first reported a position in SKYE in Q3 2024 and held it in 3 quarters. The position peaked at $416K in Q3 2024. 58 funds tracked by Wall St. Rank hold SKYE as of Q2 2025.

  • Schroder Investment Management Group reported no remaining Skye Bioscience position as of Q2 2025 after selling out during the quarter.
  • Schroder Investment Management Group sold 110,927 Skye Bioscience shares in Q2 2025, an estimated $207K.
  • Schroder Investment Management Group first reported a position in Skye Bioscience in Q3 2024 and held it in 3 quarters.
  • Schroder Investment Management Group's Skye Bioscience position peaked at $416K in Q3 2024.
  • 58 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2025.

Based on Schroder Investment Management Group's 13F filing for Q2 2025, filed 13 Aug 2025.